Krane Funds Advisors LLC Sells 1,635 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)

Krane Funds Advisors LLC lessened its holdings in HUTCHMED (China) Limited (NASDAQ:HCM) by 3.4% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 46,438 shares of the company’s stock after selling 1,635 shares during the period. Krane Funds Advisors LLC’s holdings in HUTCHMED were worth $1,824,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of HCM. Quilter Plc bought a new stake in HUTCHMED during the 2nd quarter worth approximately $1,210,000. Campbell & CO Investment Adviser LLC purchased a new stake in HUTCHMED during the 2nd quarter valued at approximately $251,000. Deutsche Bank AG grew its holdings in HUTCHMED by 10.5% during the 2nd quarter. Deutsche Bank AG now owns 181,253 shares of the company’s stock valued at $7,117,000 after buying an additional 17,195 shares in the last quarter. Susquehanna International Group LLP purchased a new position in shares of HUTCHMED in the second quarter valued at $681,000. Finally, Panagora Asset Management Inc. grew its holdings in shares of HUTCHMED by 141.2% in the second quarter. Panagora Asset Management Inc. now owns 12,501 shares of the company’s stock valued at $491,000 after purchasing an additional 7,319 shares in the last quarter. Hedge funds and other institutional investors own 26.60% of the company’s stock.

Several research analysts have commented on HCM shares. Cantor Fitzgerald lifted their price objective on shares of HUTCHMED from $40.00 to $45.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 13th. Zacks Investment Research upgraded HUTCHMED from a “sell” rating to a “hold” rating in a report on Tuesday, September 14th. The Goldman Sachs Group downgraded HUTCHMED from a “buy” rating to a “neutral” rating and set a $46.00 price objective for the company. in a report on Wednesday. Finally, Jefferies Financial Group began coverage on HUTCHMED in a report on Tuesday, August 3rd. They issued a “buy” rating and a $52.00 price objective for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, HUTCHMED has an average rating of “Buy” and a consensus target price of $44.60.

HCM traded down $0.93 on Friday, hitting $36.56. The company had a trading volume of 112,441 shares, compared to its average volume of 301,399. The stock has a fifty day moving average price of $39.91 and a 200-day moving average price of $33.40. HUTCHMED has a 12-month low of $23.67 and a 12-month high of $43.94. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.30 and a current ratio of 4.41. The stock has a market capitalization of $6.32 billion, a price-to-earnings ratio of -40.62 and a beta of 1.08.


HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products.

Featured Story: What is Depreciation?

Want to see what other hedge funds are holding HCM? Visit to get the latest 13F filings and insider trades for HUTCHMED (China) Limited (NASDAQ:HCM).

Institutional Ownership by Quarter for HUTCHMED (NASDAQ:HCM)

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with's FREE daily email newsletter.